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Abstract: Resveratrol is a naturally occurring polyphenolic compound with various pharmacological
activities. It is unknown whether the expression of metabolizing enzymes correlates with resveratrol
levels in organs and tissues. Therefore, we investigated the metabolism and tissue distribution of
resveratrol in mice and assessed its association with the expression of UDP-glucuronosyltransferase
(Ugt) and sulfotransferase (Sult) genes. Plasma, urine, feces, and various organs were analyzed using
high-performance liquid chromatography at up to 8 h after intragastric resveratrol administration.
The metabolism of resveratrol was pronounced, leading to the formation of resveratrol glucuronides
and sulfates. Concentrations of resveratrol and its metabolites were high in the gastrointestinal
organs, urine, and feces, but low in the liver and kidneys. In lung, heart, thymus, and
brain tissues, parent resveratrol levels exceeded the sulfate and glucuronide concentrations.
The formation of resveratrol conjugates correlated with the expression of certain Ugt and Sult genes.
Reverse transcription quantitative PCR (RT-qPCR) analysis revealed high mRNA expression of Ugt1a1
and Ugt1a6a in the liver, duodenum, jejunum, ileum, and colon, leading to high concentrations
of resveratrol-3-O-glucuronide in these organs. Strong correlations of resveratrol-3-O-sulfate
and resveratrol-3-O-4′-O-disulfate formation with Sult1a1 mRNA expression were also observed,
particularly in the liver and colon. In summary, our data revealed organ-specific expression of Sults
and Ugts in mice that strongly affects resveratrol concentrations; this may also be predictive in humans
following oral uptake of dietary resveratrol.
Keywords: resveratrol; metabolism; mice; Sults; Ugts; tissue distribution
1. Introduction
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a naturally occurring compound that is produced
by a wide variety of plants, berries, and fruits, and is mainly found in the skin of grapes and in red
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wine [1]. Interest in resveratrol has increased due to various studies reporting its role in improving the
outcomes of various pathologies, e.g., cardiovascular and neurodegenerative diseases, inflammation,
viral infections, and cancer [2–4]. These beneficial effects on health are observed despite extremely
low bioavailability and rapid clearance from the circulation [4,5], based on extensive metabolism in
humans and animal models [6–9]. Previously, data from our laboratory demonstrated that resveratrol
is biotransformed in the rat liver into six different products [10], with resveratrol-3-O-glucuronide,
resveratrol-3-O-4′-O-disulfate, and resveratrol-3-O-sulfate being the most abundant metabolites.
In humans, resveratrol glucuronides are the predominant biotransformation products when low
doses of resveratrol are ingested, whereas for higher doses, sulfates are mainly generated [11]. As most
resveratrol conjugates have decreased pharmacological activity, first-pass metabolism in the gut
and liver has a significant influence on the efficacy of resveratrol. Sulfation and glucuronidation of
resveratrol are carried out by UDP-glucuronosyltransferases (UGTs) and cytosolic sulfotransferases
(SULTs), respectively, and the expression levels of these enzymes have a major influence on the profile
of resveratrol conjugates generated in different organs of the body (Figure 1). Therefore, it is important
to determine the tissue-specific expression patterns of these enzymes. Previous investigations have
mainly focused on the analysis of resveratrol and its metabolites in plasma, urine, or feces [4,6,12],
as well as the distribution in various organs [9,13,14]. To the best of our knowledge, there are no data
in the literature regarding the expression of resveratrol-metabolizing enzymes in tissue samples and
their correlation with resveratrol concentrations.
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immunofluorescence on paraffin-embedded sections from control and malignant breast tissues, clearly 
indicating a correlation of RT-qPCR data with the protein expression of this enzyme. Other studies 
Figure 1. Formation of resveratrol metabolites by various UDP-glucuronosyltransferases (UGTs) and
cytosolic sulfotransferases (SULTs) in humans. Conjugates in bold represent the main metabolic pathway.
Previously, we have shown that resveratrol is selectively metabolized to resveratrol-3-O-sulfate in
12 of 13 human breast cancer tissue speci ens [15]. Reverse transcription quantitative PCR (RT-qPCR)
analysis of paired samples fro control and tu or tissues revealed A expression of SULT1A2,
SULT1A3, and S T1 , i ave all b en shown to c talyz resveratrol biotransformation [16].
As SULT1A1 mRNA expression was below the detection limit in ll samples and SULT1E1 mRNA
was only detectable in a few sampl s, the cellular localization of SULT1A3 was assessed by
indirect immunofluorescence on paraffin-embedded se tions from control and malignant breast
tissues, clearly indicati g a correlation of RT-qPCR data with the protein expression of t is enzyme.
Other studies identified the UGT1A family, including UGT1A1, UGT1A6, UGT1A7, UGT1A9,
and UGT1A10, to be responsible for catalyzing the formation of resveratrol-3-O-glucuronide and
resveratrol-4′-O-glucuronide [17,18].
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However, no data are available regarding the association of UGT and SULT mRNA expression
with resveratrol glucuronidation and sulfation in tissue samples. Therefore, in the present study,
we conducted feeding studies in mice, and time-dependently quantified resveratrol and its main
glucuronides and sulfates in plasma and selected tissues by using a sensitive high-performance liquid
chromatography (HPLC) assay. Furthermore, the mRNA expression levels of the major isoenzymes
responsible for resveratrol metabolism were investigated in order to determine the association between
tissue-specific expression and metabolite formation.
2. Material and Methods
2.1. Chemicals
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) was obtained from Sigma-Aldrich (Munich, Germany).
Resveratrol-3-O-glucuronide, resveratrol-3-O-sulfate, and resveratrol-3-O-4′-O-disulfate were obtained
from Santa Cruz Biotechnology (Dallas, TX, USA). Methanol and water were of HPLC grade and were
purchased from Merck (Darmstadt, Germany). All other chemicals and solvents were commercially
available, of analytical grade, and used without further purification.
2.2. Animal Experiments
Male wild-type C57BL/6 Oca2p−un (weight, 23–28 g) were obtained from the University of California
at Los Angeles (UCLA). Animals were housed in a temperature-, light-, and humidity-controlled
environment and fed a SSNIFF™ standard diet and water (pH 3.5) ad libitum. Resveratrol, as a
PBS solution containing 1% Tween 20 and 1% ethanol, was administered intragastrically by oral
gavage feeding in overnight-fasted mice (aged 1.5–2.5 months) at a single dose of 10 mg/kg resveratrol.
Blood samples (300 µL each) were obtained prior to sacrifice of the animals, and were collected into
EDTA-coated tubes. For the tissue distribution study, groups of mice (n = 3 per group) were sacrificed
at 0.5, 1, 1.5, 2, 4, 6, and 8 h post-dosing, respectively. Subsequently, the spleen, liver, kidney, heart, lung,
stomach, duodenum, jejunum, ileum, cecum, colon, thymus, muscle, and brain were rapidly excised
and washed with NaCl (0.9%) to remove residual blood containing resveratrol and its metabolites.
Tissues were wiped with filter paper, weighed, immediately frozen in liquid nitrogen, and maintained
at−80 ◦C until homogenization. For RT-qPCR studies, groups of four mice were used without previous
gavage. The experimental protocol was approved by the Committee on the Ethics of the Austrian
Ministry of Science (No. 66.009/122-II/10b/2010).
2.3. Sample Preparation
Following the addition of 200 µL of methanol to 100 µL of each plasma sample, samples were
centrifuged and an 80 µL aliquot of each supernatant was injected into the HPLC column. Mouse tissue
samples were thawed on ice at 4 ◦C, mixed with a threefold amount of 5 mM ammonium acetate/acetic
acid buffer (pH 7.4), and then minced using an Ultra-Turrax®-homogenizer, four times for 10 s
each, on ice. Tissue homogenates were first centrifuged at 13,000× g for 10 min, and proteins
were eliminated through a second centrifugation by adding methanol (500 µL) to 250 µL of the
supernatant. Subsequently, 80 µL of the remaining supernatant was injected onto the HPLC column.
In all cases, sample manipulation was performed while avoiding direct light exposure to prevent
possible photochemical isomerization of trans-resveratrol to the cis form.
2.4. High-Performance Liquid Chromatography (HPLC) Analysis
Resveratrol and its glucuronidated and sulfated biotransformation products were quantified
by HPLC as described previously [19] using a Dionex UltiMate 3000 system (Sunnyvale, CA, USA)
equipped with an L-7250 injector, an L-7100 pump, an L-7300 column oven (set at 15 ◦C), a D-7000
interface, and an L-7400 UV detector (Thermo Fisher Scientific, Waltham, MA, USA) set at a
wavelength of 307 nm. Calibration of the chromatogram was accomplished using the external
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standard method. Linear calibration curves were performed by spiking drug-free cell culture medium
with standard solutions of resveratrol, resveratrol-3-O-sulfate, resveratrol-3-O-4′-O-disulfate, and
resveratrol-3-O-glucuronide to give a concentration range from 0.001 to 10 µg/mL (average correlation
coefficients: >0.999). For this method, the lower limits of quantification for resveratrol and resveratrol
conjugates were 5 ng and 7 ng, respectively. Coefficients of accuracy and precision for these compounds
were <11%.
2.5. Reverse Transcription Quantitative PCR (RT-qPCR)
Total RNA was extracted from mouse tissue samples using peqGOLD Trifast™ reagent (peqLAB,
Erlangen, Germany), according to the manufacturer’s instructions. The concentration, purity, and
integrity of RNA samples were determined by UV absorbance and gel electrophoresis. Total RNA
samples (2 µg) were reverse transcribed to cDNA using random hexamer primers and a MultiScribe™
Reverse Transcriptase Kit (ThermoFisher Scientific, Waltham, MA, USA), in accordance with the
manufacturer’s instructions. RT-qPCR was performed using RT2 Profiler PCR Arrays (PAMM-069ZA,
Qiagen, Hilden, Germany) and RT2 SYBR Green qPCR Master Mix (Qiagen, Hilden, Germany) on
96-well plates in an ABI Prism® 7900HT Sequence Detection System (Thermo Fisher Scientific, Waltham,
MA, USA) to analyze mouse phase II enzymes involved in drug metabolism. In order to determine
appropriate reference genes, 5 different mouse housekeeping genes were included in the arrays, and
Hprt (validated with the Mm01545399TaqMan® Gene Expression Assays, ThermoFisher Scientific,
Waltham, MA, USA) was selected as the most appropriate reference gene. Gene expression levels were
quantified relative to the values obtained for Hprt. Data analyses were done using the web-based
analysis software from Quiagen.
2.6. Data Analysis
For the quantifications of resveratrol and its metabolites in plasma, urine, feces, and various
organs, a group of three mice was used. The area under the concentration curves from 0 to 8 h
(AUCs0–8h) was calculated using the linear trapezoidal rule with the program Phoenic WinNonlin
version 1.5 (Centera Inc., Princeton, NJ, USA). The maximal plasma, urine, feces, and tissue
concentration (Cmax) and the time after administration of resveratrol when Cmax was reached (Tmax)
were estimated from Tables 1–4. All concentrations and the values for Cmax and AUC were expressed
as mean ± SD calculated using the GraphPad Prism 6.0 (GraphPad, San Diego, CA, USA).
Table 1. Distribution of unmetabolized resveratrol in plasma (nmol/mL), various organs (nmol/g of tissue),
urine (nmol/mL), and feces (nmol/g wet content) of mice at different time-points following the intragastric
administration of a single dose of 10 mg/kg resveratrol. Maximum concentrations (Cmax values) are in bold.
Sample
Resveratrol Concentration
0.5 h 1 h 1.5 h 2 h 4 h 6 h 8 h
Plasma 0.140± 0.012 0.132 ± 0.017 0.118 ± 0.017 0.124 ± 0.041 0.135 ± 0.036 0.220 ± 0.079 0.152 ± 0.023
Spleen 4.347 ± 3.686 3.434 ± 1.946 3.305 ± 3.473 7.232± 1.050 3.218 ± 2.983 3.134 ± 1.824 2.229 ± 2.045
Liver 0.439± 0.133 0.358 ± 0.255 0.424 ± 0.217 0.345 ± 0.252 0.281 ± 0.105 0.141 ± 0.023 0.128 ± 0.033
Kidney 0.740 ± 0.361 0.786± 0.441 0.881 ± 0.436 0.418 ± 0.365 0.548 ± 0.140 0.667 ± 0.039 0.602 ± 0.137
Heart 3.698± 2.519 1.097 ± 1.094 1.176 ± 1.091 1.169 ± 1.126 1.129 ± 0.978 0.931 ± 0.339 0.276 ± 0.147
Lung 3.505± 2.985 1.791 ± 0.699 1.968 ± 1.769 1.899 ± 2.056 0.857 ± 0.749 2.388 ± 1.989 1.827 ± 1.300
Stomach 128.9± 74.38 111.8 ± 52.42 71.18 ± 60.49 40.93 ± 35.12 5.065 ± 2.220 1.709 ± 1.490 2.600 ± 1.072
Duodenum 10.01± 4.763 4.505 ± 2.787 6.551 ± 4.581 0.984 ± 0.081 0.752 ± 0.210 1.651 ± 0.673 1.100 ± 0.452
Jejunum 3.590± 1.692 1.693 ± 0.854 2.386 ± 2.288 0.889 ± 0.261 0.485 ± 0.133 0.715 ± 0.044 0.985 ± 0.515
Ileum 8.435 ± 2.611 26.17± 19.12 6.411 ± 2.166 2.074 ± 1.421 1.513 ± 0.512 1.289 ± 1.120 2.428 ± 1.751
Cecum 22.66 ± 15.47 11.52 ± 4.843 163.5± 138.5 30.72 ± 16.22 29.05 ± 19.92 1.761 ± 1.569 2.587 ± 2.235
Colon 7.422 ± 2.339 2.292 ± 1.390 22.04± 10.64 10.34 ± 6.731 9.754 ± 5.745 0.862 ± 1.087 2.655 ± 0.496
Thymus 15.01 ± 8.971 15.21± 6.934 4.784 ± 1.286 2.857 ± 0.192 0.818 ± 0.314 2.351 ± 1.051 11.01 ± 4.994
Muscle 1.530± 0.824 0.680 ± 0.619 0.557 ± 0.489 0.695 ± 1.203 0.555 ± 0.483 0.163 ± 0.128 0.333 ± 0.177
Brain 0.484± 0.337 0.212 ± 0.167 0.127 ± 0.054 0.041 ± 0.014 ND ND ND
Urine 4.716 ± 0.057 3.510 ± 0.513 15.70± 11.85 0.779 ± 0.106 5.091 ± 3.238 5.455 ± 2.562 4.472 ± 2.398
Feces 49.62 ± 29.79 186.5 ± 135.1 171.8 ± 79.23 292.5 ± 156.6 336.9± 219.2 22.24 ± 14.37 15.58 ± 13.93
Data are expressed as the mean ± SD; n = 3. ND: not detected.
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Table 2. Distribution of resveratrol-3-O-glucuronide in plasma (nmol/mL), various organs (nmol/g of tissue),
urine (nmol/mL), and feces (nmol/g wet content) in mice at different time-points following the intragastric
administration of resveratrol at a single dose of 10 mg/kg. Maximum concentrations (Cmax values) are
in bold.
Sample
Resveratrol-3-O-Glucuronide Concentration
0.5 h 1 h 1.5 h 2 h 4 h 6 h 8 h
Plasma 0.289± 0.102 0.081 ± 0.055 0.082 ± 0.040 0.076 ± 0.021 0.037 ± 0.019 0.090 ± 0.045 0.016 ± 0.011
Spleen 0.785 ± 1.360 1.908± 1.305 1.767 ± 1.061 ND ND ND ND
Liver 2.173± 1.120 0.758 ± 0.488 0.984 ± 0.333 0.821 ± 0.380 0.480 ± 0.201 0.059 ± 0.101 0.057 ± 0.056
Kidney 2.665± 2.066 2.119 ± 1.598 1.556 ± 0.702 1.749 ± 0.759 0.351 ± 0.377 0.329 ± 0.048 0.202 ± 0.190
Heart 2.155± 1.284 0.370 ± 0.640 0.230 ± 0.398 0.269 ± 0.467 0.198 ± 0.114 0.145 ± 0.112 ND
Lung 6.440± 2.566 1.179 ± 0.658 1.527 ± 0.781 2.459 ± 0.471 0.185 ± 0.120 0.124 ± 0.095 ND
Stomach 72.69± 41.68 35.83 ± 10.97 21.93 ± 7.397 8.483 ± 3.440 2.754 ± 1.625 0.898 ± 0.786 1.140 ± 1.396
Duodenum 46.03± 36.63 15.96 ± 11.51 26.49 ± 13.38 3.761 ± 0.734 1.553 ± 1.101 0.672 ± 0.599 0.445 ± 0.241
Jejunum 11.30± 7.849 3.658 ± 2.922 10.74 ± 2.962 2.610 ± 2.396 0.946 ± 0.508 0.291 ± 0.234 0.183 ± 0.060
Ileum 35.07 ± 7.835 118.6± 49.70 12.26 ± 0.822 3.282 ± 2.030 1.716 ± 0.814 0.492 ± 0.440 0.594 ± 0.328
Cecum 1.528 ± 1.299 0.702 ± 0.653 0.627 ± 1.085 3.167± 2.962 ND ND ND
Colon 1.845 ± 0.530 0.707 ± 0.540 4.385± 5.582 3.830 ± 3.202 0.805 ± 0.394 ND ND
Thymus 12.39± 2.539 ND ND ND ND ND ND
Muscle 0.683± 0.673 0.642 ± 0.090 0.622 ± 0.299 0.342 ± 0.309 0.232 ± 0.101 ND ND
Brain ND ND ND ND ND ND ND
Urine 362.7 ± 86.98 522.5± 289.7 440.1 ± 146.9 147.5 ± 78.32 168.1 ± 118.9 120.5 ± 51.62 96.92 ± 36.83
Feces 22.60± 9.050 ND ND ND ND 1.524 ± 1.321 9.743 ± 1.216
Data are expressed as the mean ± SD; n = 3. ND: not detected.
Table 3. Distribution of resveratrol-3-O-sulfate in plasma (nmol/mL), various organs (nmol/g of tissue),
urine (nmol/mL), and feces (nmol/g wet content) in mice at different time-points following the
intragastric administration of resveratrol at a single dose of 10 mg/kg. Maximum concentrations
(Cmax values) are in bold.
Sample
Resveratrol-3-O-Sulfate Concentration
0.5 h 1 h 1.5 h 2 h 4 h 6 h 8 h
Plasma 0.265± 0.141 0.089 ± 0.049 0.160 ± 0.142 0.148 ± 0.102 0.055 ± 0.026 0.069 ± 0.049 0.023 ± 0.011
Spleen 0.558± 0.966 ND ND ND ND ND ND
Liver 1.649± 0.975 0.596 ± 0.347 1.081 ± 0.428 0.991 ± 0.493 0.739 ± 0.409 0.070 ± 0.122 0.070 ± 0.068
Kidney 1.525 ± 0.724 1.602± 1.726 0.885 ± 0.244 1.055 ± 0.489 0.594 ± 0.374 0.378 ± 0.366 0.295 ± 0.282
Heart 2.405± 1.166 1.517 ± 0.954 1.922 ± 1.031 0.627 ± 0.085 ND ND ND
Lung 4.877± 3.653 0.848 ± 0.771 1.271 ± 1.105 2.741 ± 1.465 ND ND ND
Stomach 96.16± 38.23 45.50 ± 21.81 36.51 ± 30.13 7.719 ± 4.434 3.605 ± 1.059 3.043 ± 1.057 4.332 ± 0.968
Duodenum 67.25± 27.95 27.08 ± 11.75 59.21 ± 34.83 8.202 ± 2.905 3.141 ± 1.562 1.358 ± 1.179 0.910 ± 0.868
Jejunum 13.24 ± 7.097 6.847 ± 4.393 16.05± 12.51 6.451 ± 3.212 2.370 ± 1.228 0.828 ± 0.637 0.497 ± 0.275
Ileum 73.23 ± 19.10 178.2± 125.5 41.65 ± 15.54 13.48 ± 8.766 6.577 ± 4.057 2.198 ± 0.852 1.583 ± 1.495
Cecum 12.67 ± 3.839 2.883 ± 2.691 24.94± 13.31 12.58 ± 8.254 3.829 ± 1.946 0.590 ± 0.122 0.123 ± 0.213
Colon 2.189 ± 0.749 0.929 ± 0.603 6.117± 2.114 5.133 ± 3.381 1.646 ± 1.982 ND ND
Thymus 28.31± 14.53 ND ND ND ND ND ND
Muscle 0.209 ± 0.363 0.217± 0.162 0.196 ± 0.339 ND ND ND ND
Brain ND ND ND ND ND ND ND
Urine 128.3± 33.15 108.5 ± 51.50 62.23 ± 15.03 54.72 ± 25.74 58.73 ± 3.598 52.40 ± 12.57 22.15 ± 7.149
Feces 41.64 ± 13.96 32.85 ± 5.838 6.733 ± 1.380 52.64± 12.72 11.21 ± 9.740 2.796 ± 0.435 21.55 ± 8.708
Data are expressed as mean ± SD; n = 3. ND: not detected.
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Table 4. Distribution of resveratrol-3-O-4′-O-disulfate in plasma (nmol/mL), various organs
(nmol/g of tissue), urine (nmol/mL), and feces (nmol/g wet content) in mice at different
time-points following the intragastric administration of resveratrol at a single dose of 10 mg/kg.
Maximum concentrations (Cmax values) are in bold.
Sample
Resveratrol-3-O-4′-O-Disulfate Concentration
0.5 h 1 h 1.5 h 2 h 4 h 6 h 8 h
Plasma 0.099± 0.016 0.090 ± 0.028 0.039 ± 0.023 0.050 ± 0.044 0.033 ± 0.022 0.042 ± 0.037 0.049 ± 0.033
Spleen ND ND ND ND ND ND ND
Liver 0.585± 0.258 0.267 ± 0.143 0.422 ± 0.100 0.517 ± 0.073 0.218 ± 0.036 0.019 ± 0.032 0.021 ± 0.037
Kidney 0.430 ± 0.252 0.692 ± 0.516 0.387 ± 0.113 0.986± 0.720 0.767 ± 0.101 0.247 ± 0.182 0.078 ± 0.046
Heart 0.406 ± 0.203 0.973± 0.332 ND ND ND ND ND
Lung 0.673± 0.867 0.275 ± 0.177 0.164 ± 0.102 0.438 ± 0.258 ND ND ND
Stomach 15.08± 9.413 4.088 ± 3.812 4.899 ± 3.492 1.448 ± 0.834 1.389 ± 0.556 0.251 ± 0.234 0.350 ± 0.076
Duodenum 12.54± 6.672 5.273 ± 4.943 5.080 ± 3.785 1.092 ± 0.104 0.956 ± 0.306 0.203 ± 0.176 0.123 ± 0.113
Jejunum 1.666± 1.280 1.210 ± 0.841 1.233 ± 1.175 0.665 ± 0.191 0.527 ± 0.315 0.166 ± 0.098 ND
Ileum 2.264 ± 0.441 2.594 ± 0.577 2.749± 1.006 1.474 ± 0.938 1.219 ± 0.518 0.260 ± 0.150 0.270 ± 0.168
Cecum 0.363 ± 0.319 0.280 ± 0.485 0.807 ± 0.706 1.123± 0.991 0.305 ± 0.328 ND ND
Colon 0.751 ± 0.287 0.377 ± 0.136 0.843± 0.505 0.632 ± 0.433 ND ND ND
Thymus ND ND ND ND ND ND ND
Muscle 0.167 ± 0.089 0.327± 0.167 0.255 ± 0.214 ND ND ND ND
Brain ND ND ND ND ND ND ND
Urine 7.382 ± 0.362 53.17 ± 23.97 10.19 ± 3.056 50.06 ± 24.88 67.57 ± 33.96 106.0± 48.06 58.26 ± 23.76
Feces 11.92± 2.654 6.930 ± 2.455 1.767 ± 0.060 1.821 ± 0.155 1.989 ± 0.446 7.778 ± 3.473 3.155 ± 5.465
Data are expressed as the mean ± SD; n = 3. ND: not detected.
3. Results
3.1. Tissue Levels of Resveratrol and Its Conjugated Metabolites
Mice received intragastric resveratrol (10 mg/kg), and the levels of resveratrol and its main
metabolites (resveratrol-3-O-sulfate, resveratrol-3-O-4′-O-disulfate, and resveratrol-3-O-glucuronide)
were measured in the plasma, urine, and feces and in gastrointestinal organs (stomach, duodenum,
jejunum, ileum, colon), the immune system (spleen), and the liver, kidney, heart, lung, thymus, muscle,
and brain, respectively. Tables 1–4 summarize the concentrations of resveratrol and its metabolites
in mouse tissues collected at 0.5, 1, 1.5, 2, 4, 6, and 8 h after intragastric resveratrol administration.
The results indicate that resveratrol and its metabolites were rapidly and widely distributed in the body.
In all tissues, except the spleen, kidney, ileum, cecum, colon, and thymus, resveratrol levels
peaked at 30 min. The highest levels were observed for the cecum (163.5 nmol/g) after 1.5 h, and the
stomach (128.9 nmol/g) after 30 min, exceeding the levels in the liver and brain by up to 300-fold.
Peak values in the ileum and kidneys were reached after 1 h.
Similar observations were made for the glucuronidated and sulfated resveratrol metabolites.
Resveratrol-3-O-glucuronide levels were highest in the stomach and duodenum after 30 min, and
were even higher in the ileum after 1 h, at levels 30- to 50-fold higher than those in the spleen and
muscle. The concentration of resveratrol-3-O-sulfate was also highest in the stomach and duodenum
after 30 min (96.2 nmol/g), and in the ileum after 1 h (178.2 nmol/g).
As shown in Table 4, resveratrol-3-O-4’-O-disulfate concentrations were highest in the stomach
and duodenum after 30 min and in the ileum after 1 h, reflecting the patterns exhibited by resveratrol
and the two aforementioned metabolites. Interestingly, all glucuronidated and sulfated metabolites
were undetectable in brain tissues.
Resveratrol levels in the plasma were low and peaked at 30 min. The same was true for
the metabolites; an approximately threefold-higher concentration was observed in the plasma for
resveratrol-3-O-glucuronide and resveratrol-3-O-sulfate compared with resveratrol 3-O-4’-O-disulfate.
Contrary to in the plasma, resveratrol and its conjugates were found at high concentrations in the feces;
resveratrol levels in the urine were negligible.
Table 5 shows the area under the time curves (AUC) of plasmatic, urinary, fecal, and tissue
concentrations of resveratrol and its metabolites for the 8 h immediately following resveratrol
administration. The highest resveratrol-3-O-glucuronide concentrations were predominantly detected
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in the urine. The most obvious change in resveratrol and its metabolite concentrations occurred in the
spleen, in which the AUC for resveratrol was 99.7 times higher than that for resveratrol-3-O-sulfate.
In general, the amount of resveratrol-3-O-4′-O-disulfate formed was low compared with the two other
metabolites, and was below the detection limit in the spleen, thymus, and brain. However, in the ileum
and urine, the AUCs of resveratrol-3-O-4′-O-disulfate were 1.6 and 22 times higher, respectively, than
that for free resveratrol.
Table 5. Area under the concentration–time curves (AUCs) (0–8 h) for plasma, urine, feces, or
tissues of resveratrol (Res), resveratrol-3-O-glucuronide (Res3G), resveratrol-3-O-sulfate (Res3S), and
resveratrol-3-O-4′-O-disulfate (ResDiS) in mice that received resveratrol (10 mg/kg) intragastrically.
Sample
AUC (nmol/mL min or nmol/g min)
Res Res3G Res3S ResDiS AUCRes/AUCRes3G AUCRes/AUCRes3S AUCRes/AUCResDiS
Plasma 1.21 ± 0.72 0.59 ± 0.22 0.71 ± 0.28 0.37 ± 0.15 2.05 1.70 3.27
Spleen 27.8 ± 4.35 2.23 ± 1.91 0.28 ± 0.16 n.a. 12.5 99.7 n.a.
Liver 2.02 ± 0.44 4.12 ± 2.17 4.59 ± 1.65 1.78 ± 0.56 0.50 0.44 1.13
Kidney 4.76 ± 0.88 6.92 ± 2.67 5.56 ± 1.60 3.60 ± 0.99 0.69 0.86 1.32
Heart 8.84 ± 3.70 2.00 ± 1.16 1.99 ± 1.41 0.83± 0.37 4.41 4.45 10.6
Lung 14.3 ± 3.51 8.27 ± 3.44 6.92 ± 2.88 1.02 ± 0.67 1.73 2.07 14.0
Stomach 223 ± 118 84.3 ± 32.7 116 ± 46.2 17.5 ± 5.08 2.65 1.92 12.8
Duodenum 17.7 ± 10.1 53.8 ± 26.0 96.9 ± 37.3 15.3 ± 6.54 0.33 0.18 1.16
Jejunum 8.33 ± 3.59 18.8 ± 11.3 33.0 ± 16.1 4.27 ± 1.67 0.44 0.25 1.95
Ileum 31.1 ± 16.2 92.1 ± 38.6 182 ± 98.2 8.43 ± 3.96 0.34 0.17 0.62
Cecum 201 ± 63.5 5.39 ± 3.17 44.9 ± 24.9 2.74 ± 1.12 37.4 4.48 73.5
Colon 52.7 ± 22.0 9.87 ± 4.39 14.3 ± 6.12 1.21 ± 0.84 5.34 3.68 43.5
Thymus 34.9 ± 12.7 6.19 ± 2.26 14.2 ± 8.35 n.a. 5.63 2.46 0.0
Muscle 4.02 ± 1.53 2.37 ± 0.68 0.76 ± 0.21 0.74 ± 0.17 1.70 5.31 5.45
Brain 0.46 ± 0.18 n.a. n.a. n.a. n.a. n.a. n.a.
Urine 38.8 ± 13.6 1521 ± 411 462 ± 103 503 ± 141 0.03 0.08 0.08
Feces 1304 ± 337 24.1 ± 12.6 156 ± 52.6 35.3 ± 11.9 54.1 8.36 37.0
Data are expressed as mean ± SD; n = 3. n.a.: not applicable.
Figures 2 and 3 provide an overview of resveratrol and its three main metabolites in the plasma,
liver, kidney, heart, lung, and brain during the time course of 8 h. As shown in Figure 2A, parent
resveratrol and resveratrol-3-O-glucuronide peaked in the plasma at 30 min, with a second peak at 6 h,
which indicates enterohepatic recirculation. In the liver and kidneys (Figure 2A,B), resveratrol and its
conjugates decreased and were markedly low after 6 h, particularly in the liver. Differences were also
observed in the distribution of resveratrol in the heart and lungs, where resveratrol concentrations only
slightly decreased, or even increased, after 6 h (Figure 3A,B). As shown in Figure 3C and in Tables 2–4,
parent resveratrol was found in the brain (but its metabolites were not), with a maximal concentration
after 30 min, followed by a rapid decline.
Figure 4 gives an overview of the total amount (calculated as the percentage of the applied
dose) of resveratrol and its metabolites in mouse tissue samples, plasma, urine, and feces during the
time of the experiment (0–8 h). We quantified 21.3% of the metabolites in the gastrointestinal tract,
of which the most abundant metabolite was resveratrol-3-O-sulfate (12.4% of the initial resveratrol
amount administered). Interestingly, ~11% of the unconjugated resveratrol was detected in the
stomach, duodenum, jejunum, cecum, and colon. The recovery of resveratrol, resveratrol-3-O-sulfate,
resveratrol-3-O-4′-O-disulfate, and resveratrol-3-O-glucuronide was 0.7, 1.0, 1.4, and 4.4% in
the urine, and 11.9, 1.4, 0.3, and 0.2% in the feces, respectively. Only ~2% of the dose was
recovered as resveratrol-3-O-glucuronide or resveratrol-3-O-sulfate from all organs analyzed, whereas
approximately 1.5% was quantified as unconjugated resveratrol.
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3.2. Expression of Sult and Ugt Genes in Mouse Tissues and Organs
To investigate the expression of enzyme systems that may be involved in the phase II metabolism
of resveratrol, RT-qPCR analyses were performed for 9 Sult and 12 Ugt genes in selected mouse organs.
In accordance with previous data on the differences in Ugt and Sult expression in mouse organs [20–22],
we identified organ-specific expression of different isoforms (see Figure 5). From the Ugt family 1,
Ugt1a1, Ugt1a2, Ugt1a6a, and Ugt2b34 mRNAs were highly expressed in the liver and intestines
(duodenum, jejunum, ileum, and colon). Ugt2a3, a member of the Ugt family 2, was expressed in the
liver, duodenum, and jejunum, but was negligible in the ileum and not detected the colon. Ugt2b38 and
Ugt2b5 were observed at high levels in the liver and spleen, respectively, and at considerably lower
levels in the duodenum and brain, while Ugt2b1 mRNA expression appeared to be liver-specific.
Ugt8a mRNA expression was high in the liver and brain, whereas Ugt3a1 was expressed at only
low levels in the liver, spleen, colon, and brain. Ugt2a1 mRNA expression in all tissue samples was
below the detection limit, and a very low level of Ugt2b37 expression was detectable only in the liver
and spleen.
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Figure 5. Expression map showing mRNA expression of various Sults and Ugts in tissue samples from
mice. The image map (Java TreeView [23]) shows the pattern of enzyme expression as determined
by reverse transcription quantitative PCR relative to the expression of Hprt (selected as the most
appropriate reference gene).
The expression of the Sult1a1 gene, the mouse homolog of human SULT1A1, was highest in the
liver, followed by the colon, spleen, and brain. Sult1b1 and Sult2b1 mRNAs were primarily expressed
in the intestines (duodenum, jejunum, ileum, and colon), while Sult1c2 mRNA expression was highest
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in the colon, followed by the kidney. Interestingly, Sult4a1, Sult5a1, and Sult6B1 mRNAs exhibited
selective expression in the brain, liver, and spleen, respectively. Sult1c1 and Sult6b1 mRNA transcripts
were below the detection limit in all investigated tissue samples.
4. Discussion
In the present study, tissue distribution of resveratrol and its three major metabolites (resveratrol-3-
O-sulfate, resveratrol-3-O-4′-O-disulfate, and resveratrol-3-O-glucuronide) in the plasma, urine, feces,
and tissues of mice was investigated in male mice after oral administration of resveratrol (10 mg/kg).
A single dose of 10 mg/kg was chosen based on the daily intake of resveratrol as dietary
supplement (100–500 mg/day) to humans. Furthermore, data from our lab also showed that higher
resveratrol concentrations inhibit the formation of resveratrol-3-O-sulfate, which might also be
observed in mice [24]. We decided to use male and not female mice in all experiments as recent
papers [25,26] described significant gender-dependent differences in the glucuronidation of drugs and
flavonoids in mice, with a higher formation rate of glucuonides in females than in males, which might
be also true for resveratrol. In humans, such pronounced gender-difference in glucuronidation has not
been observed so far.
Despite the numerous studies that have investigated the plasmatic levels of resveratrol and
its metabolites in mice, very few have attempted to assess the tissue distribution of this natural
compound. Therefore, to the best of our knowledge, the present study constitutes the first report of the
time-dependent distribution of resveratrol and its major metabolites in 14 tissues as well as in feces
and urine in mice following intragastric administration. No data about the concentration of resveratrol
and its conjugates in the spleen, thymus, and muscle have been published so far. Furthermore, we also
performed, for the first time, a comparison of concentrations with the presence of phase II metabolizing
enzymes in appropriate tissues and organs. The liver, kidneys, and gastrointestinal tract are organs
with a high phase II metabolizing activity [27]. After oral administration of resveratrol, our experiments
showed that resveratrol was detected predominantly in its glucuronic-acid- and sulfate-conjugated
forms in these organs (Figure 4). High levels of resveratrol conjugates could be detected already in
the stomach by resveratrol-metabolizing gastric cells. The lower concentration of the three conjugates
in the cecum and colon might be due to a decreased expression of the efflux transporters multidrug
resistance protein 2 (MRP2) and breast cancer resistance protein (BCRP), as both membrane proteins
are substrates for resveratrol and its conjugates [28,29]. Both transporters are able to pump resveratrol
glucuronides and sulfates back into the lumen as previously shown in rats [30]. Interestingly, the
overall concentration of resveratrol was higher than that of its metabolites in the stomach, cecum,
colon, spleen, heart, lung, thymus, and muscle, as well as in the fecal samples (Figure 4). A recent
paper of Menet et al. [31] confirmed our results also showing higher resveratrol concentration in mouse
heart tissue. This is in contrast to other authors who found higher levels of conjugates in the hearts of
rats and pigs [9,13].
The same is true for the lung, for which Juan et al. [32] also showed higher resveratrol
concentrations, whereas Lin et al. [13] could only detect conjugates. Interestingly, in the lung, we
could only quantify resveratrol at low levels; the concentration of all three metabolites was below
the detection limit. The observed poor accumulation of resveratrol in the brain might be explained
by the presence of MRP2 and BCRP in the blood–brain barrier, preventing a pronounced uptake
into the brain. No detectable resveratrol conjugates in the brain are in line with findings in pigs
shown after intragastric administration of 6.5 mg/kg of resveratrol [9]. Other authors, however, could
not detect resveratrol and its conjugates in rat and mouse brains [13] or found up to six-fold higher
resveratrol-3-O-sulfate concentration compared with that of native resveratrol [33]. This discrepancy
might be explained by altered doses or different sample preparation steps prior to analysis.
As mentioned above, higher resveratrol concentrations might inhibit resveratrol-3-O-sulfate
formation and also change the pattern of metabolites. Indeed, a single dose of 150 mg/kg to
mice resulted in up to 5.8-fold higher resveratrol-3-O-glucuronide concentrations in mouse hearts
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30 min and 60 min after dosing [31], whereas our data showed slightly higher concentrations of
resveratrol-3-O-sulfate levels at the same time points.
Interestingly, tissue, feces, and urine levels of resveratrol and its conjugates did not show the
expected decline with time after dosing. This might be explained either with a delayed transport of
resveratrol from the stomach to the colon or by a redistribution between organs. This would explain
the high concentration in the thymus for free resveratrol after 8 h. A second peak in the plasma after
6 h for unconjugated resveratrol is possibly caused by enterohepatic recirculation of free resveratrol
cleaved by β-glucuronidase from resveratrol 3-O-glucuronide after biliary excretion. The maximum
concentration of the final metabolic product resveratrol-3-O-4′-O-sulfate in the urine after 6 h, however,
can be explained by its longer formation time starting from resveratrol via resveratrol-3-O-sulfate and
resveratrol-4′-O-sulfate.
In humans, resveratrol glucuronidation is mainly catalyzed by UGT1A1 and UGT1A9, and, to
a minor extent, by UGT1A6, UGT1A7, and UGT1A10 [18,34], whereas sulfation is performed by
SULT1A1, SULT1A2, SULT1A3, and SULT1E1 [15,16]. Although there are no data available in the
literature regarding the conjugation of resveratrol glucuronides and sulfates by mouse-specific Ugts and
Sults, several studies have demonstrated high homology between mouse and human isoenzymes, at
least for Ugt1a1, Ugt1a6a, and Sult1A1, with a similarity in the amino acid sequence of 75–90% [35,36],
which suggests comparable enzymatic activity for resveratrol.
In the present study, the formation of resveratrol glucuronides and sulfates correlated with
the expression of certain Ugts and Sults. RT-qPCR analysis revealed high mRNA expression of
Ugt1a1 and Ugt1a6a in the liver, duodenum, jejunum, and ileum, leading to high concentrations of
resveratrol-3-O-glucuronide in these organs. High expression of Ugt1a1 and Ugt1a6a in the liver and
small intestines of mice is in accordance with previously reported data [20,22]. A good correlation of
resveratrol-3-O-sulfate and resveratrol-3-O-4′-O-disulfate formation with Sult1a1 mRNA expression
was also observed, particularly in the liver and colon.
Ugt1a2 and Ugt2b34 were highly expressed in the liver, duodenum, jejunum, and ileum, whereas
Sult4a1 mRNA was almost exclusively detected in the brain. Whether Sult2b1, Ugt1a2, and Ugt2b34
also catalyze resveratrol sulfation and glucuronidation is not yet known. However, based on their
high expression in the liver and gastrointestinal tract, we assume the involvement of these isoforms
in the metabolism of resveratrol in mouse organs. Our data are in line with previous reports also
demonstrating high mRNA expression of Ugt2b5 and Ugt2b1 in the liver and of Ugt2b38 in the
kidney [36]. Contrary to a study by Saiki et al., which reported the expression of Sult1b1 mRNA
exclusively in the liver, the present findings revealed Sult1b1 mRNA expression in the small and large
intestines in mice [37]. This discrepancy may be explained by the fact that the authors used a Northern
blot analysis and not the more sensitive RT-qPCR. RT-qPCR analysis may therefore be predictive for
the metabolism in tissue samples. Low or no detectable expression of Ugts and Sults, as observed
in the spleen, heart, and lung, consequently led to an overall far higher percentage of resveratrol
compared with those of its conjugates.
The different distribution of resveratrol and its conjugates in various tissues may be predictive
for the observed pharmacological activities of resveratrol. In organs like the spleen, heart, lung,
muscle, and brain, resveratrol concentrations might be far too low for any significant biological effect.
Although resveratrol glucuronides and sulfates are less active than resveratrol, they may act as a depot,
easily converted back to resveratrol by ubiquitously existing human β-glucuronidase and sulfatases.
The expression of UGTs and SULTs in the tissues therefore helps to predict the overall pharmacological
activity of resveratrol.
Another option to improve oral bioavailibity of resveratrol and, consequently, its efficacy is
the inhibition of the glucuronidation in the intestine by UGT-inhibitors. Co-administration of the
UGT inhibitor piperin increased the AUC and Cmax of resveratrol in rat plasma by 229% and 1544%,
respectively [38]. This pronounced effect was also observed when resveratrol was administered by a
nanoemulsion composed of soybean oil, soy lecithin, and the UGT inhibitor labrasol, again increasing
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the Cmax and bioavailability approximately 11- and 5-fold, respectively [39]. These strategies might
help to increase concentrations in organs for which we show minor accumulation of resveratrol.
5. Conclusions
In conclusion, the present study demonstrated organ-specific metabolization of resveratrol into its major
conjugates—resveratrol-3-O-glucuronide, resveratrol-3-O-sulfate, and resveratrol-3-O-4′-O-disulfate—in
mice. Metabolite concentration correlated with the distribution of Sult and Ugt genes, which may be
predictive in humans after the dietary administration of resveratrol. Therefore, further in vivo studies
should focus on the concentration of resveratrol and its metabolites in target tissues, and also take into
account the expression levels of enzymes involved in resveratrol conjugation.
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